Menu
Innovation Observatory > Reports > Drugs > IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma

< Back

IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma

Drugs

Cancer and Palliative Care

December 2017


There are currently few effective treatments available for advanced or metastatic uveal melanoma, including surgery to remove the cancer, radiotherapy or chemotherapy. IMCgp100 is a drug under development that would enable the body’s own immune system to recognise and specifically target and kill cancer cells. IMCgp100 is given by intravenous infusion and is currently being studied in patients with advanced/ metastatic uveal melanoma. It will offer a new treatment option if licenced.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

IMCgp100 for Metastatic Uveal Melanoma



Load More Related Posts
Get Alerts